
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Katie Greenlee, PharmD, BCPS-AQ Cardiology, of the Cleveland Clinic discusses the role of platelet aggregation inhibitors in ACS management.
Katie Greenlee, PharmD, BCPS-AQ Cardiology, of the Cleveland Clinic discusses the role of platelet aggregation inhibitors in ACS management.
This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.






